Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 31 May 2022
FDA approves label extension for Evrysdi for infants with spinal muscular atrophy under 2 months old
31 May 2022 - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to ...
Posted by Michael Wonder on 31 May 2022
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
31 May 2022 - Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry ...
Posted by Michael Wonder on 31 May 2022
FDA accepts Dupixent (dupilumab) for priority review in adults with prurigo nodularis
31 May 2022 - Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., ...
Posted by Michael Wonder on 31 May 2022
Xbrance provides update on ranibizumab biosimilar candidate FDA filing
30 May 2022 - Xbrane Biopharma has withdrawn its biologics license application for its investigational biosimilar candidate to Lucentis after ...
Posted by Michael Wonder on 30 May 2022
Health insurance faces handbrake under Labor: UBS
30 May 2022 - A rebound in the number of Australians taking out private health insurance may slow under Labor’s ...
Posted by Michael Wonder on 30 May 2022
ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
27 May 2022 - ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative ...
Posted by Michael Wonder on 30 May 2022
Why won’t the FDA let doctors prescribe fluvoxamine for COVID?
30 May 2022 - Trials show it keeps patients from getting sicker, but the agency won’t approve its emergency use. ...
Posted by Michael Wonder on 30 May 2022
Takeda says drug makers could cut prices in face of global crises
30 May 2021 - The head of Asia’s largest pharmaceutical company said the risk of a global recession, along with ...
Posted by Michael Wonder on 30 May 2022
2022 Biosimilar Awareness Week: 30 May – 3 June
30 May 2022 - Marking a new dawn in medicine choice and affordability. ...
Posted by Michael Wonder on 30 May 2022
Illuccix reimbursement milestone and launch updates: pass-through status granted in the U.S.
30 May 2022 - Telix Pharmaceuticals today provides an update on the U.S. and Australian launch and reimbursement status for ...
Posted by Michael Wonder on 30 May 2022
NICE sets out further details on menopause guideline update
27 May 2022 - NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where ...
Posted by Michael Wonder on 29 May 2022
$2,000,000,000 profit shows private health insurance reform needed to tackle cost of living crisis
26 May 2022 - The Medical Technology Association of Australia has pointed to the record profits for insurance companies as ...
Posted by Michael Wonder on 29 May 2022
ATAGI update following weekly COVID-19 meeting (25 May 2022)
27 May 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 25 ...
Posted by Michael Wonder on 29 May 2022
Application accompanying data collection in the case of market access for several active substances in a class: IQWiG presents a concept
27 May 2022 - The institute recommends platform studies under a master's protocol. ...
Posted by Michael Wonder on 29 May 2022
EUnetHTA relative effectiveness assessments: efforts to increase usability, transparency and inclusiveness
26 May 2022 - The objective of the European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 (JA3) was to ...